Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CONMED Corp Director's Dealing 2013

Jun 4, 2013

31971_dirs_2013-06-04_a6ef964c-5dcc-48a1-b560-d8f3f92cdcc3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CONMED CORP (CNMD)
CIK: 0000816956
Period of Report: 2013-06-01

Reporting Person: SCHWARTZ STUART J (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2013-06-01 Common Stock M 200 Acquired 4400 Direct
2013-06-01 Common Stock M 3000 Acquired 7400 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2013-06-01 Rsus (restricted Stock Units) $0 M 200 Disposed 2019-06-01 Common Stock (200) Direct
2013-06-01 Rsus (restricted Stock Units) $0 M 3000 Disposed 2022-06-01 Common Stock (3000) Direct
2013-06-01 Rsus (restricted Stock Units) $0 A 3000 Acquired 2023-06-01 Common Stock (3000) Direct
2013-06-01 Sars (Stock Appreciation Rights) $32.93 A 1000 Acquired 2023-06-01 Common Stock (1000) Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2007 Amended and Restated Non-Employee Director Equity Compensation Plan, with the RSUs generally vesting 20% per year over a five year period, with any unvested RSUs to vest and be delivered upon the Director's termination of service provided the Director has completed one full year of service since the date of the award.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2007 Amended and Restated Non-Employee Director Equity Compensation Plan, with the RSUs generally vesting 100% after a one year period.

F3: The stock appreciation rights ("SARs") were granted under the Company's 2007 Amended and Restated Non-Employee Director Equity Compensation Plan, with the SARs generally vesting 100% after a one year period.